Lupin Limited (NSE:LUPIN) disclosed on 28 August 2026, via a Regulation 30 filing, that Crisil ESG Ratings and Analytics Ltd has independently assigned the pharmaceutical company an ESG Rating of Crisil ESG 69 and a Core ESG Rating of Crisil Core ESG 65 for FY26, placing it in the Strong category.
Key Highlights
- Crisil ESG Ratings and Analytics Ltd assigned Lupin an ESG Rating of Crisil ESG 69 for FY26, placing the company in the Strong category.
- A Core ESG Rating of Crisil Core ESG 65 was also awarded independently for the same financial year, covering environmental, social, and governance dimensions.
- The rating was prepared independently by Crisil ESG Ratings using publicly available information; Lupin did not commission or engage Crisil for this assessment.
- The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, filed with both NSE and BSE.
About the Company
Lupin Limited (NSE:LUPIN), headquartered at Santacruz (East), Mumbai, is one of India's largest pharmaceutical companies by revenue. The company manufactures and markets branded and generic formulations, active pharmaceutical ingredients, and biotechnology products across more than 100 countries. Its key therapeutic areas include cardiovascular, anti-diabetic, anti-infective, and respiratory segments, supported by manufacturing plants across India, the United States, and other global locations.
Announcement in Detail
In its filing dated 28 August 2026, Lupin Limited informed exchanges that Crisil ESG Ratings and Analytics Ltd had independently assigned the company an ESG Rating of Crisil ESG 69 and a Core ESG Rating of Crisil Core ESG 65 for FY26. Both ratings place Lupin in the Strong category under Crisil's classification framework. The filing explicitly states that Lupin did not engage or commission Crisil ESG Ratings for this assessment; the rating agency prepared its report solely on the basis of publicly available information about the company.
The ESG Rating of 69 and the Core ESG Rating of 65 represent Crisil's independent evaluation of Lupin's performance across environmental stewardship, social responsibility, and governance practices for the financial year ended March 2026. The disclosure was made by Amit Kumar Gupta, Company Secretary and Compliance Officer, in accordance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, which requires listed entities to promptly inform stock exchanges of material developments including ratings received from recognised agencies.
Impact on Investors
Investors will note that the Crisil ESG 69 rating, assigned independently without any engagement or payment by Lupin, may carry additional credibility compared to ratings directly commissioned by the rated entity. The filing shows that the Strong category designation reflects a favourable assessment of Lupin's environmental, social, and governance practices for FY26 based on publicly available disclosures.
Shareholders will observe that ESG ratings are increasingly referenced by institutional investors, ESG-focused funds, and index providers when making allocation decisions. The disclosed terms indicate that the rating pertains solely to FY26 and does not constitute any forward-looking commitment by Crisil or Lupin regarding future ESG performance or financial outcomes.
Sector / Market Context
ESG disclosures and third-party ESG ratings have become increasingly prominent in India's pharmaceutical sector following SEBI's mandate requiring the top 1,000 listed companies by market capitalisation to file Business Responsibility and Sustainability Reports annually. Industry bodies such as FICCI and CII have noted growing institutional demand for credible, independently verified ESG data across healthcare and pharma supply chains, particularly from foreign portfolio investors and ESG-aligned mutual funds operating in Indian equity markets.